Open AccessEfficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
Author(s) -
Kutsch Nadine,
Pallasch Christian,
Tausch Eugen,
Böhme Volkmar,
Ritgen Matthias,
Liersch Rüdiger,
Wacker Alexander,
Jacobs Georg,
Trappe Ralf Ulrich,
Dreger Peter,
Fischer Kirsten,
Fink AnnaMaria,
Stilgenbauer Stephan,
Zhai Shuyan,
Li Biao,
Jürgensmeier Juliane M.,
Rajakumaraswamy Nishanthan,
Bhargava Pankaj,
Hallek Michael,
Eichhorst Barbara F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000692
Subject(s) - bruton's tyrosine kinase , obinutuzumab , idelalisib , chronic lymphocytic leukemia , ibrutinib , medicine , syk , tyrosine kinase , chemoimmunotherapy , cancer research , tolerability , oncology , leukemia , pharmacology , immunology , adverse effect , receptor